Response-Adapted Benefit of Postoperative Adjuvant Therapy Following Neoadjuvant Treatment in Resectable NSCLC: A Single-Center Retrospective Cohort Study.

Cancers (Basel) · 2026 · PMC13025113 · PMID 41899557

Europe PMC DOI

hedged sentence

0.0110

closest p · 0.2× alpha

0.0110

boldest claim

The sentences

a clear trendp = 0.011actually significant

The results remained consistent: patients with poor pathological response (ypIIA/IIIA) exhibited significantly higher recurrence risks, and intensified adjuvant IO + Chemo showed a clear trend toward superior EFS ( p = 0.011, Supplementary Figures S1 and S2 ). 3.5.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.